Abstract | Chronic kidney disease (CKD) is defined by persistent urine abnormalities, structural abnormalities or impaired excretory renal function suggestive of a loss of functional nephrons. The majority of patients with CKD are at risk of accelerated cardiovascular disease and death. For those who progress to end-stage renal disease, the limited accessibility to renal replacement therapy is a problem in many parts of the world. Risk factors for the development and progression of CKD include low nephron number at birth, nephron loss due to increasing age and acute or chronic kidney injuries caused by toxic exposures or diseases (for example, obesity and type 2 diabetes mellitus). The management of patients with CKD is focused on early detection or prevention, treatment of the underlying cause (if possible) to curb progression and attention to secondary processes that contribute to ongoing nephron loss. Blood pressure control, inhibition of the renin-angiotensin system and disease-specific interventions are the cornerstones of therapy. CKD complications such as anaemia, metabolic acidosis and secondary hyperparathyroidism affect cardiovascular health and quality of life, and require diagnosis and treatment.
. Examples of structural abnormalities include cysts, tumours, malformations and atrophy, which are evident on imaging. By contrast, kidney dysfunction can manifest as hypertension, oedema, changes in output or quality of urine and growth delay in children; these changes are most often recognized by increased serum levels of creatin ine, cystatin C or blood urea nitrogen. The most common pathological manifestation of CKD, regard less of the initiating insult or disease, is some form of renal fibrosis.
The Kidney Disease Improving Global Outcomes (KDIGO) initiative classifies an individual as having CKD if abnormalities of kidney structure or function persist for >3 months. KDIGO describes a classification of severity, defining numerous stages of CKD on the basis of glomer ular filtration rate (GFR; either estimated (eGFR) or meas ured (mGFR)) and the extent of albumin uria 1 (FIG. 1) .
GFR and albuminuria are used to classify CKD because GFR is a wellestablished marker of renal excretory func tion and albuminuria is an indicator of renal barrier dysfunction (glomerular injury). Both have been found to be reliable predictors of longterm CKD outcomes.
As the kidney comprises many independent functional and anatomical 'units' (nephrons), GFR can be expressed by the equation: GFR (total) = GFR (singlenephron) × number of nephrons, whereby GFR (singlenephron) is the filtration cap acity of single nephrons. This equation implies that when the number of nephrons declines, total GFR will not change as long as the remaining nephrons can increase their contribution. By contrast, a decline in total GFR implies a considerable loss of nephrons with remnant nephrons possibly operating at their maximum pos sible GFR (singlenephron) . As such, CKD usually represents a loss in nephron number. Furthermore, the KDIGO categor ies (FIG. 1) describe the risk of progression to kidney failure -that is, endstage renal disease (ESRD), which would require renal replacement therapy (perito neal dialysis, haemodialysis or kidney transplantation) -and a number of other adverse outcomes that include risk of cardiovascular disease (CVD), death, acute kidney injury (AKI), infection and hospitalization. The KDIGO staging has proven to be instrumental in deci sion making on patient management but is not without controversy
.
Although classifying the severity of CKD by GFR and albuminuria is useful, identifying the risk factors or underlying causes of CKD (BOX 2) is essential for optimal management and is recommended by current guidelines 1 . CKD is associated with numerous compli cations such as anaemia, metabolic acidosis (reduced acid excretion by the kidneys) and CVD, which increase the complexity of patient management. In this Primer, we discuss the global prevalence of CKD; the different diseases that can contribute to poor nephron endow ment or nephron loss; the pathophysiology of CKD progression; the diagnosis, screening and prevention of CKD; and CKD management to improve outcomes and quality of life. Finally, we describe several research domains potentially offering improvements for CKD management in the near future.
Epidemiology

Prevalence
The prevalence of all stages of CKD varies between 7-12% in the different regions of the world 3 . CKD G3-G5 prevalence in adults varies worldwide, with values reported as 1.7% in China 4 , 3.1% in Canada 5 , 5.8% in Australia 6 and 6.7% in the United States 7 . In Europe, the prevalence ranges from 2.3% in Germany 8 , 2.4% in Finland 9 , 4.0% in Spain 9 to 5.2% in England 10 . The variability in these numbers is a point worthy of fur ther study and might be attributable to different reasons (for example, some studies might use a single time point (therefore not fulfilling the definition of CKD)); accord ingly, whether prevalence has been over estimated or underestimated is unclear 11 . The epidemio logy of CKD in low and middleincome countries (LMICs) is poorly characterized owing to the lack of communitybased studies, inconsistent assessment of kidney function and nonstandardized or non calibrated approaches 12 . Nevertheless, in southeast Asia, some Latin American countries (such as Mexico) and in subSaharan Africa, when assessed, the prevalence of CKD seems to be con sistent with the estimates of 10-16% [12] [13] [14] . Notably, most prevalence data are based on GFR only, without con sideration of albuminuria, in line with the first CKD classification system reported in 2002.
Little is known about CKD in children because of the absence of registries and because children are not included in many clinical studies. In Europe, the 2014 incidence of paediatric ESRD was 5.7 per million age related population (pmarp) in children aged 0-14 years; the prevalence was 32.2 pmarp 15 . Earlier estimates sug gested the incidence and prevalence were 8.3 pmarp and 58.0 pmarp, respectively, in children aged 0-19 years 16 , which is lower than 14.7 pmarp and 103.9 pmarp for the age group 0-21 years in the United States 17 . In high income countries, congenital disorders of the urinary tract (CAKUT) are responsible for the majority of cases of paediatric CKD; by contrast, acquired causes, such as infection and glomerular diseases, predominate in LMICs 18 .
Risk factors
CKD (all stages) is most common in people >65 years of age, but the probability of progression to ESRD is higher in younger people (≤65 years of age) with CKD 3 . Interestingly, although the prevalence of CKD is higher in women than in men, men are more likely to pro gress to ESRD 3 . The most common underlying diseases associ ated with CKD are diabetes mellitus and hyperten sion, particularly in highincome and middleincome countries. In those with diabetes, CKD prevalence is estimated at 30-40%; whether CKD in these individ uals is caused by their diabetes per se or by micro vascular dis ease as a consequence of diabetes is not known. However, in LMICs, CKD is associated with infectious diseases, glomerulo nephritis (a group of diseases that lead to inflammation of the glomerulus) and inappropriate use of medications (such as traditional remedies with potential nephro toxins, NSAIDs and nephrotoxic antibiotics) 19, 20 . In LMICs, current trends in socioeconomic status and an ageing population will increase the absolute number of people with CKD and the diabetes and obesity epi demic might eventually take over as the main aetiological cause for CKD. Furthermore, low birthweight (typically defined as <2,500 g) due to preterm birth or intrauterine growth restriction is associated with CKD later in life; the global risks of preterm birth and low birthweight are ~10% and ~15%, respectively. Thus, millions of children are born at risk of CKD later in life and are found at the lower percentile of agematched GFR (that is, they are typically among the youngest patients with CKD) 21, 22 . Populations who are at increased risk of CKD include Aboriginal Australians, African Americans, people of Spanish decent in central and South America, indigen ous populations in Canada, south Asians, east Asians and Pacific Islanders; these populations are at risk owing to genetic factors or to the interaction of genetic and environmental factors 23 . Endemic forms of CKD suggest regional triggers, which are often difficult to define but might include specific infections, toxins, behaviours or climate related factors 24 . Reports of chronic interstitial nephri tis or CKD of undetermined origin in sugar cane and other agricultural workers in Latin America, Sri Lanka, India, Cameroon, Mexico and Australia are examples of this phenomenom [24] [25] [26] .
Kidney replacement therapy
Often, countries do not know the number of patients with CKD but do have information on the use of renal replacement therapies (see Management) 27 , which can be used to estimate the number of patients with CKD. However, appropriate data on ESRD can only be obtained from countries with dialysis registries; such data are missing from LMICs in particular, where registries do not exist. In 2014, the incidence of kidney replace ment therapy varied from 49 per million population (pmp) in Bangladesh to as high as 455 pmp in Taiwan 17 . Considerable vari ation has also been reported in the preva lence of kidney replacement therapy, from 113 pmp in Bangladesh to 3,219 pmp in Taiwan 17 (FIG. 2) .
Dialysis is the first type of kidney replacement therapy for the majority of patients, because preemptive trans plantation as an initial modality is not freely available. Globally, haemodialysis is most commonly used 17, 28 -the exception being Hong Kong, where peritoneal dialysis is the preferred choice of dialysis treatment 29 . Kidney trans plantation rates differ substantially between countries, from 1 pmp in Bangladesh to 60 pmp in Jalisco, Mexico 30 . In many European countries, >50% of patients on renal replacement receive transplants 17, 28 , which contrasts with parts of Asia (such as Taiwan, Japan and the Philippines) where kidney transplantation is rarely performed 17 . The reasons why transplantation is not available include cul tural preferences, socioeconomic factors and health care infrastructure deficiencies (for example, lack of biopsy services, surgeons or immunology laboratories).
The availability of dialysis and transplantation ser vices has not been systematically documented. However, the Global Kidney Health Atlas gives an overview of the availability of kidney replacement therapy worldwide 30 (full report available at www.theisn.org), although these data do not reflect the actual need for kidney replace ment therapy. Estimates of unmet need are in the range 2-7 million people per year 31 . Furthermore, availability and accessibility are not the same -even when services are available, not all individuals have access to them for reasons that include cost reimbursement, demand and specific policies. Accordingly, many individuals do not receive renal replacement therapy despite having reached ESRD. Estimates of dialysis incidence and preva lence based on current data worldwide are, therefore, imprecise owing to inequities in access. Future studies should strive to determine numbers of dialysiseligible individuals, not just those who receive the treatment.
Mortality
Reports from the Global Burden of Disease study indi cate an increasing burden of CKD over the past 20 years (with substantial worldwide variation) to which diabetes is the most important contributor 32, 33 . CKD as a cause of mortality has also increased over the past 25 years (from being ranked 25th in 1990 to 17th in 2015) and now con tributes 1.35% of the global burden of disability life years lost, growing at a rate of 1% per year 32, 34, 35 . Again, these data are largely based on the first CKD classification sys tem that excluded albuminuria from the CKD definition. This Kidney Disease Improving Global Outcomes (KDIGO) 2D matrix incorporates the level of albuminuria (given as a ratio to creatinine (in mg per g) and divided into three categories) and the glomerular filtration rate (GFR) -that is, the level of kidney function -to describe the risk of patients with chronic kidney disease (CKD) progressing to adverse outcomes (such as progression to end-stage renal disease (ESRD), cardiovascular disease, hospitalization, acute kidney injury or death). Notably, in primary care settings, proteinuria is generally measured rather than measuring albuminuria specifically; however, the proteinuria dipstick results can be used to approximate the albuminuria stages. Additionally, GFR can either be estimated using various clinical equations or directly measured using dyes. The KDIGO matrix defines different stages of CKD referred as, for example, CKD G2A2 whereby the GFR is 60-89 ml/min/1.73 m 2 and albuminuria is moderately increased; such a patient would have a moderately increased risk of progressing to ESRD. However, the staging for CKD G2-G4 might underestimate the extent of irreversible nephron loss 257 . For example, if total GFR relies on the filtration capacity of single nephrons (GFR (single-nephron) ) and the number of nephrons, GFR (single-nephron) has to increase to compensate for nephron loss to maintain total GFR. However, full compensation is no longer possible with ongoing nephron loss as occurs with physiological ageing 76 and total GFR declines owing to further reductions in nephron number. Additionally, serum creatinine underestimates nephron loss because it increases late in the disease process, when more nephrons are lost than would be implied by GFR alone. Finally, the prognostic value of the matrix suffers from being based on studies potentially having a false-positive rate of ~30-35% owing to a lack of repeat analysis after 3 months (that is, true CKD diagnoses were not consistently obtained) 41 . Mortality increases with decreasing eGFR and increas ing albumin uria 36 and is highest in patients on kidney replacement therapy; 5year survival of those on dialysis is 40-50% 17, 28 with similar survival between haemodialy sis and peritoneal dialysis 37 . Patients receiving a kidney transplant have better prospects, with a 5year survival of 86% in those receiving a deceased donor kidney and 93% in those receiving a kidney from a living donor. Life expectancy for those on dialysis (either modal ity) is onethird of that of the agematched and sex matched general popu lation; life expectancy is 45-85% of that of the general population for those who receive a kidney transplant 17, 28 .
Mechanisms/pathophysiology
Nephron loss Nephrons are generated in weeks 12-36 of gestation in humans, with a mean of 950,000 nephrons per kidney (with a range of ~200,000 to >2.5 million) 38 . No new neph rons can be generated after this period. During growth, the available nephrons increase in size to accommodate increased renal demands. Furthermore, GFR decreases with age (FIG. 3a) . Although nephrons can contend with transient increases in filtration load (as with food and fluid intake) by transiently increasing GFR (singlenephron) without structural changes (a display of 'renal reserve') 39, 40 , longer or persistent increases in body mass (for example, during pregnancy or obesity) promote nephron hypertrophy (mostly comprising increased dimensions of the glomerular tuft, Bowman's capsule and the proximal tubule) as the compensatory mechanism. Nephron loss, for example owing to injury or donation of one of the kidneys, can have the same hypertrophic effect on the remaining nephrons. Indeed, either severe kidney injury or combinations of injury with ageing related neph ron losses -especially in individ uals with poor nephron endowment and/or obesity -acceler ates persistent increased GFR (singlenephron) and loss of remnant nephrons 41 .
Nephron hypertrophy. Remnant nephron hypertrophy is triggered by persistent elevations of GFR (singlenephron) and filtration pressure (that is, glomerular hypertension) across the glomerular filtration barrier, which implies glomeru lar hyperfiltration. Glomerular hyperfiltra tion and glomerular hypertension together induce the expression of transforming growth factorα and epithe lial growth factor receptor 42, 43 , which promote nephron hypertrophy that, in turn, reduces glomerular hyper tension by increasing the filtration surface 44 . Indeed, increased GFR (singlenephron) and remnant nephron hyper trophy enable kidney donors to maintain an apparently 'normal' renal function, despite lacking 50% of their nephrons. Obviously, kidney donation does not neces sarily cause CKD when donors are carefully selected for good nephron endowment, the absence of obesity, diabetes and other sources of nephron injury 45, 46 . However, in other circumstances, hyperfiltrationdriven increases in glomerular size can potentially be harm ful 44, 47, 48 . Beyond a certain threshold of hypertrophy, increasing shear stress on podocytes (which are key octopus shaped cells that maintain the glomerular fil tration barrier of the nephron) promotes podocyte detachment, focal segmental glomerulosclerosis (FSGS, a pathological entity in which renal injury results in sclero tic lesions in segments of glomeruli), global glomerulo sclerosis and subsequent nephron atrophy, a vicious cycle that further reduces nephron number and increases the GFR (singlenephron) of remnant nephrons 42, 44, [49] [50] [51] [52] (FIG. 4) .
Impaired glomerular filtration.
Angiotensin II prod uction and mechanistic target of rapamycin (mTOR) signalling maintain persistent podocyte hypertrophy and glomerular hyperfiltration and ultimately aggrav ates podocyte loss and proteinuria. Angiotensin II is a peptide hormone that is part of the renin-angiotensin system (RAS) that drives vasoconstriction and aldoster one secretion (and, therefore, sodium retention and an increase of blood pressure). Aldosterone, in turn, directly impairs the glomerular barrier sieving function, possibly by inhibiting expression of the podocyte pro tein nephrin, which is a structural component of the slit diaphragm necessary for maintaining the glomerular filtration barrier 53 . Angiotensin II possibly also contrib utes to the dysregulated response of progenitor parietal epithelial cells along Bowman's capsule, generating FSGS lesions instead of replacing lost podocytes 54 . This struc tural remodelling of the glomerulus presents clinically as protein uria, which is a marker of nephron damage and is predictive of CKD progression (defined as a GFR decline of >5 ml/min/1.73 m 2 per year or sevenfold the normal rate of loss with ageing 42, 55, 56 .
Fibrosis. Nephron loss involves nonspecific wound healing responses that include interstitial fibrosis (FIG. 5) . Infiltrating immune cells, albuminuria and, in diabetes, glucosuria, activate proximal tubular epithelial cells, resulting in the secretion of proinflammatory and pro fibrotic mediators that promote interstitial inflammation and fibrosis 57 . Interstitial fibrosis seems to drive further nephron injury through the promotion of renal ischae mia 57 , but -as in other organs -scar formation might also mechanically stabilize the remaining nephrons 58 . The increased tubular transport workload of remnant Box 1 | Thresholds, age and CKD Whether chronic kidney disease (CKD) should be diagnosed and staged using absolute thresholds irrespective of age remains controversial 248, 249 . The glomerular filtration rate (GFR) in healthy adults 20-40 years of age is ~107 ml/min/1.73 m 2 and declines at a rate of ~0.7 ml/min/1.73 m 2 per year 250, 251 . Accordingly, by 75 years of age, many otherwise healthy individuals (without major comorbidities) will have lost 50% of their nephrons and their GFR will be half that of when they were 25 years of age 252 . Indeed, a substantial number of older healthy individuals have 'low' GFR (that is, <60 ml/min/1.73 m 2 ) but normal albuminuria (that is, a Kidney Disease Improving Global Outcomes (KDIGO) CKD classification of G3aA1 (FIG. 1) ), which is associated with having only a small increase in relative risk of all-cause mortality 253, 254 . The threshold of GFR that should be used to detect CKD in younger people is similarly controversial 116 . nephrons also involves anaerobic metabolism, intra cellular acidosis and endoplasmic reticulum stress, which promote secondary tubular cell injury 42, 59 .
Contributing factors
Several factors can contribute to the pathogenesis of CKD, including low birthweight, pregnancy, obesity, diabetes and ageing. These scenarios contribute different factors that lead to and/or exacerbate nephron loss, promoting the cycles of injury and ultimately resulting in ESRD.
Prematurity and low birthweight. Newborn babies with low birthweight frequently display incomplete kidney development 60, 61 ; poor nephron endowment can cause CKD at any age [60] [61] [62] [63] . Indeed, one study documented that for every 13 individuals born at low birthweight in the United States, one had reduced GFR and one had raised systolic blood pressure, the risks for which increased with age 22 . The infants who are born <2,500 g in weight face a fourfold higher risk of being diagnosed with CKD by the time they are 17 years of age than those born weighing ≥2,500 g (REF. 62 ). CKD at puberty is common in these individuals when rapid body growth exceeds the capacity of nephron number to accommodate the increasing fil tration load 64 . In milder cases, poor nephron endowment at birth promotes the development of arterial hyperten sion, diagnosis of CKD later in adults or a morerapid progression of glomerulonephritis to ESRD 22, 61, 65 (FIG. 3b) .
All of these factors increase the risk of CVD.
Genetic factors. Genetic abnormalities can cause CKD by fostering nephrocalcinosis 66 or cystic degeneration, by weakening epithelial integrity or by abnormal process ing or storage of metabolites or glycoproteins 67, 68 . CAKUT are the most common congenital abnormalities, resulting in kidney hypodysplasia, low nephron count and risk of CKD [69] [70] [71] . Aside from CAKUT, ciliopathies, cystic kidney diseases, tubulopathies and podocytopathies can cause CKD 68, [70] [71] [72] . Genetic testing has revealed that ~20% of earlyonset CKD (defined as CKD manifesting before 25 years of age) can be attributed to a monogenic cause 72 . Until recently, monogenic causes of CKD were mostly reported in children or adolescents, but genetic variants also contribute as cofactors to CKD progression in adults (FIG. 6) In general, the association between obesity and poor renal outcomes persists even after adjustments for higher blood pressure and diabetes, suggesting that obesitydriven glomerular hyperfiltration directly con tributes to nephron loss 77, 78 . Various fat tissuederived hor mones as well as obesityrelated systemic inflamma tion might also contribute. Morbid obesity (BMI >35 kg per m 2 ) or moderate obesity in combination with other factors (such as genetic variants, low nephron number or advanced age) can lead to development of proteinuria, secondary FSGS and progressive CKD 77, [79] [80] [81] (FIG. 6) .
Pregnancy. The last trimester of pregnancy involves volume expansion (that is, an increase in blood volume) that increases total GFR by 50% 82 , implying a respective increase of GFR (singlenephron) . These physiological adapta tions are transient and without consequences in women with normal nephron number. However, in women with low nephron endowment or previous injury related CKD (such as in women with lupus nephritis), pregnancy related glomerular hyperfiltration exacerbates rem nant nephron glomerular hyperfiltration and glomeru lar hypertrophy. In some patients, pregnancy related glomeru lar hyperfiltration in the final trimester passes the threshold of compensation and triggers rapid CKD progression, presenting with proteinuria and arterial hypertension -a condition known as preeclampsia. Preexisting CKD during pregnancy is a wellknown risk factor for preeclampsia, eclampsia (in which seizures occur), premature birth, intrauterine growth restriction and neonatal mortality 83 .
Diabetes. Diabetes is a wellknown condition associ ated with massive glomerular hyperfiltration, as evident from increased total GFR and renomegaly 48 . Hypergly caemia promotes the sodium/glucose cotransporter 2 (SGLT2)driven reabsorption of sodium in the proximal tubule, a process that subsequently inactivates tubulo glomerular feedback and activates the RAS at the macula densa in the renal tubule 84, 85 . The result is induction of a permanent dilatation of the afferent arteriole and vasoconstriction of the efferent arteriole -increasing GFR (singlenephron) and total GFR 86 . Although diabetesdriven glomerular hyperfiltration can be counteracted for many years in younger patients with normal nephron number, it serves as a drastic acceler ator of singlenephron hyperfiltration in those with low nephron endowment, injuryrelated or ageing related nephron loss or obesity or in those who are pregnant 87 . Unfortunately, this is a highly prevalent com bination of risk factors in older patients with type 2 diabe tes, for which dual SGLT2 and RAS inhibition can elicit potent nephroprotective effects by reducing glomeru lar hyperfiltration as well as proximal tubular work load as well as other potentially protective mechanisms 88 .
AKI. AKI is a clinical syndrome defined by an acute deterior ation of renal function either due to prerenal (for example, hypovolaemic shock), intrarenal (direct renal parenchymal injury) or postrenal (obstruction of urinary tract) disturbances. AKI results in the accumu lation of metabolic waste and toxins, subsequent uraemic complications and possible failure of other organs 89 .
AKI is highly prevalent in hospitalized patients and can imply irreversible losses in nephron number 90 . In western countries, AKI occurs mostly in outpatient and inpatient settings; the inpatient setting (which includes patients in intensive care) has been the focus of multiple studies showing a strong association between AKI and CKD. The causes of outpatient AKI are infections, dehydration and medications. In hospitals, AKI can be attributed to these same factors as well as to exposures to nephro toxins and is mostly observed in patients with multi ple comorbidities 91 . By contrast, in LMICs and tropical countries, prerenal AKI occurs frequently outside the hospital setting following episodes of diarrhoea, infec tion and obstetric complications 92 . Nephrotoxins can also cause AKIrelated nephron loss regardless of setting, for example, in neonates treated with aminoglycosides and in patients with cancer receiving chemotherapy.
Ageing. The decline of GFR with age (FIG. 3a) might relate to physiological ageing, genetic factors, arterial hyperten sion, diseases implying kidney injury, increase in body weight or a combination of these factors. Histologically, kidney ageing presents as global glomerulo sclerosis, the respective atrophy of entire nephrons and subsequent interstitial fibrosis 50, 76 . Whether ageing related neph ron loss is associated with hypertrophy (and glomerular Nature Reviews | Disease Primers hyperfiltration) of remnant nephrons is not consist ently reported in the literature 50, 76 , but the analytical difficulties in precisely assessing nephron number and glomerular volume and how the different functions of juxta medullary versus cortical nephrons are acknow ledged can affect the interpretation of such data 50, 76 . Ageing is also associated with decreasing podocyte density and total numbers 50 .
Systemic complications of CKD
The kidney is involved in several complex processes important in homeostasis of blood, bone integrity, acidbase balance, electrolyte levels and blood pressure. As nephron number declines, patients experience compli cations associated with dysregulation of many of these systems such as metabolic acidosis, anaemia, mineral bone disorder (MBD, which is associated with vita min D deficiency, hyperparathyroidism, hyperkalaemia and hyperphosphataemia), arterial hypertension, hyper uricaemia and expansion of effective circulating fluid volume. Dyslipidaemia, endocrine abnormalities and growth impairment in children can also occur. Of these complications, CVD is the leading cause of death in patients with CKD worldwide 34 and is associated with dyslipidaemia, hyperuricaemia and hypertension. Nonspecific symptoms of these effects include fatigue, anorexia, weight loss, pruritis (itch), nausea, vomiting, muscle cramping, oedema and shortness of breath.
Interestingly, not all individuals experience these issues at the same point in the progressive loss of kidney function; some individuals maintain excellent tubu lar and excretory function. Additionally, not all of the derangements are symptomatic, and the severity of the symptoms varies between individuals.
Fluid and electrolyte abnormalities. Derangement of sodium and water handling can become evident at all stages of CKD, with a tendency to become more severe at lower levels of kidney function. Increased accumula tion of fluid (hypervolaemia) can be overt or occult, and manifests as arterial hypertension, oedema and/or short ness of breath (alone or in combination). Some patients, including those with nephronophthisis (an auto somal recessive disease characterized by chronic tubulo inter stitial nephritis) or obstructive uro pathy, have an impaired ability to concentrate urine and have symp toms of polyuria (large volume of urine, and consequent frequent urination). Defects in urine c oncentration increase the risk of hypovolaemia.
Potassium excretion is dependent upon an exchange with sodium at the distal tubule. Accordingly, low GFR decreases the delivery of sodium to the distal tubule, decreasing the potassium exchange into the urine and leading to hyperkalaemia. Other contributory factors for hyperkalaemia include high dietary potassium intake, catabolic conditions with increased tissue breakdown, metabolic acidosis with or without secondary type IV renal tubular acidosis, decreased renin production by the juxtaglomerular apparatus and hypoaldosteronism related to RAS inhibitorrelated impaired cellular uptake of potassium.
Anaemia. The causes for anaemia in CKD are multi factorial and include reduced renal erythropoietin prod uction, reduced lifespan of red blood cells, impaired intestinal iron absorption mediated by hepcidin (a key regulator of iron circulation) and repetitive blood losses in patients on haemodialysis. Hence, the anaemia of CKD is usually normocytic (with normally sized red . P values from 0.03 to 0.97 represent the percentiles of the eGFR distribution across the age range of the entire population at a given time point, with P = 0.50 representing the mean. Horizontal lines correspond to the GFR values for the chronic kidney disease (CKD) G1-G5 stages as in FIG. 1. At 70 years of age, the nephron number is ~50% of that at 25 years of age, but whether this reduction implies increased filtration capacity of single nephrons (GFR (single-nephron) , that is, single-nephron hyperfiltration) among remnant nephrons or reflects a reduced demand for filtering metabolic waste is debated. Regardless of which process is in play, the nephron loss and total GFR also depends on comorbidities, such as obesity and history of acute kidney injury episodes. b | Low birthweight (LBW) increases the risk of developing CKD; here, LBW is associated with a shorter time to end-stage renal disease (ESRD) in patients with IgA nephropathy (HR 2.0; 95% CI 1.0-3.7; P = 0.03) 63 . Part a is adapted with permission from REF. 41 , Elsevier. Part b is adapted from REF. 63 . blood cells) and normochromic (with normal haemo globin levels inside red blood cells). By comparison, the finding of microcytosis might reflect iron deficiency or aluminium excess whereas macrocytosis can be associ ated with vitamin B 12 or folate deficiency. Anaemia in CKD is associated with fatigue, weakness, reduced attentiveness, drowsiness and low exercise tolerance.
MBD.
Chronic kidney disease-mineral bone disorder (CKD-MBD) encompasses abnormalities in mineral metabolism, bone structure and extraskeletal calcifi cations that occur with progressive CKD. Patients with mild CKD (CKD G2) can have reduced serum 25hydroxyvitamin D and/or 1,25dihydroxyvitamin D₃ levels, and an elevated serum parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) level 93 -the key hormones that regulate bone integrity and mineral (calcium and phosphate) homeostasis. Patients with advanced CKD-MBD might have bone pain, dif ficulty walking and/or skeletal deformities as well as a higher risk of fracture 94 . In children, growth retardation is a common manifestation of MBD as well as CKDrelated changes on the hormonal system.
Metabolic acidosis.
Metabolic acidosis is related to the fall in total renal ammonium excretion that occurs when the GFR decreases to <40-50 ml/min per 1.73 m 2 (CKD G3). In addition, both titratable acid excretion (primarily as phosphate) and bicarbonate reabsorption are reduced. As the patient approaches ESRD, the serum bicarbonate concentration stabilizes (to 12-20 mEq/l), which is thought to contribute to bone demineraliza tion, muscle wasting and the progression of CKD. In children, metabolic acidosis has a negative impact on growth.
Hyperuricaemia. Elevated uric acid levels can develop in patients with CKD due to decreased urinary excre tion. Serum uric acid >7.5 mg per dl is an independent risk factor for accelerated progression of CKD. Whether treating hyperuricaemia can improve renal outcomes remains to be assessed in an adequately powered randomized, placebocontrolled, doubleblind trial.
Arterial hypertension. In the majority of patients, arterial hypertension is not a cause but a consequence of CKD 95, 96 . Hypertension can be present in the earliest stages of CKD and is well documented to contribute to cardiovascular morbidity and mortality. The preva lence of hypertension is high in children with CKD (54-70% of patients) 97 . Hypertension is a consequence of activ ation of the neurohumoral axis (namely, catecho lamine and aldosterone activity), RAS activation and hyper volaemia. In some cases, arterial hypertension arises from cortico steroids or calcineurin inhibitors used to treat the underlying kidney disease. Control ling arterial hypertension is a central element of CKD management to prevent CVD. In response to nephron loss, glomerular hypertension induces an increase in nephron size (through the activation of the renin-angiotensin system (RAS) and activities of transforming growth factor-α (TGFα) and epidermal growth factor receptor (EGFR)) as a compensatory mechanism to maintain total the glomerular filtration rate and to reduce intraglomerular pressure. Accordingly, podocytes need to undergo hypertrophy to maintain the filtration barrier along the enlarged filtration surface. However, podocyte hypertrophy is limited; beyond a certain threshold, barrier dysfunction first manifests as mild proteinuria. At later stages of chronic kidney disease (CKD), the increasing podocyte shear stress promotes podocyte detachment. Parietal epithelial cells (PECs) are putative podocyte progenitors but proteinuria and potentially other factors inhibit their potential to replace lost podocytes; instead, scar formation is promoted in the form of focal segmental glomerulosclerosis (FSGS). . CKDrelated posttranslational modifications of lipid particles (the nature of which are not well character ized) imply proinflammatory effects and endothelial dysfunction 99 . The relative contribution of individual abnormalities to the accelerated development of CVD in patients with CKD remains to be defined in detail.
CVD. The high incidence of CVD in CKD can be attrib uted to the high prevalence of hypertension, dyslipid aemia, hyperuricaemia, abnormal glucose metabolism, obesity, systemic inflammation and oxidative stress. Young adults (25-34 years of age) with CKD have at least a 100fold higher risk of CVDrelated mortality compared with the general population 100 . The CKDrelated cardiovascular alterations resem ble an accelerated ageing process that is associated with a shortening of telomere length 101 . The mech anisms underlying the accelerated vascular and cardiac calcifi cation found in CKD and ESRD are only partially under stood. In early CKD (CKD G1-G2), atherosclero tic processes (such as macrophage invasion, plaque for mation and arterial wall thickening) dominate; as CKD progresses, inflammatory factors and media calcifi cation contribute to vascular wall degeneration. The different factors involved cause distinct changes in the risk factor profile and contribute differently to outcomes during the course of CKD. Additionally, left ventricular hyper trophy (either concentric (in the presence of arterial hypertension) or eccentric (in the presence of hyper volaemia and anaemia)) and dilatation can occur, leading to systolic and diastolic dysfunction. Early and sustained induction of FGF23 has been shown to be a driver of left ventricular hypertrophy in CKD 102 .
In individuals with CKD who have not commenced renal replacement therapy, the risk of cardio vascular events is as high as that of people with established coronary artery disease 103 . Risk increases with insulin resistance 104 , increased blood pressure, vascular calcifi cation 105, 106 , inflammation and protein-energy wast ing 107 . Haemodialysis can have a direct negative effect on the heart, a phenomenon referred to as myocardial stunning in which transient episodes of ischaemia are experienced 108 . As a consequence, cardiovascular mor tality is several times higher in patients with low GFR or in patients who are on haemodialysis than in the general popu lation. Accordingly, risk factors for CVD should be managed intensively in the predialysis period, during transition and at dialysis initiation.
Endocrine dysfunction. In patients with CKD, several endocrine systems become dysfunctional as kidney func tion progressively deteriorates. Abnormalities in gonadal hormones can result in reduced fertility and sexual prob lems in men and women. These abnormalities result in delayed puberty in twothirds of adolescents with ESRD 109 . Endorgan resistance to growth hormone due to decreased renal breakdown of insulin growth factor binding proteins seems to play a major part in growth impairment in children with CKD 110 . Abnormalities in thyroid function are common in CKD at all ages, but their functional importance remains under debate 111 .
Uraemia. At the onset of ESRD, untreated patients can experience anorexia, vomiting, weakness and fatigue, which are collectively referred to as symptoms of urae mia. Uraemia is a systemic inflammatory state that is thought to contribute to ESRDrelated CVD, mal nutri tion, sarcopenia, osteoporosis and frailty 2, 107 . CKD related intestinal barrier dysfunction causing bacterial endotoxin leakage into the circulation, but also dialysis related or infectionrelated immune activation, can contribute to this problem 112, 113 . Neurological changes encompass peripheral neuropathy and central nervous system abnormalities, including loss of concentration, lethargy, seizures, coma and death 2 . In adults, cognitive alterations predominate, whereas in children, develop ment of all neurocognitive domains is affected 114 , which can lead to severe intellectual disability or subtle deficits. Daytime sleepiness and fatigue are common and increase with decreasing kidney function. Restless leg syndrome can disturb sleep, but sleepdisordered breathing, exces sive daytime sleepiness and insomnia disorder are also common 115 .
Diagnosis, screening and prevention
The clinical presentation of CKD depends on the under lying disorder and the severity of renal impairment. Patients with early stages of CKD (G1-G2) are usually asymptomatic, but from CKD G3 onwards, patients may experience weakness related to anaemia and polyuria.
Detection and diagnosis CKD can be detected during a routine periodic health assessment, during evaluation of individuals at risk of CKD
, as a consequence of the incidental finding of abnormal laboratory values in connection with another acute or chronic illness, during an investigation of symp toms and/or signs relating to the kidneys or urinary tract (such as haematuria) or after discovery of abnormal laboratory values in a populationbased screening pro gramme. Importantly, the two bio chemical parameters -GFR and albuminuria -used in the KDIGO matrix 1 define and classify a 'generic' form of CKD; adding an aetiological diagnosis is both highly desirable and recommended by KDIGO (the socalled cause/GFR/ albuminuria (CGA) classification system) whenever pos sible, such that the underlying conditions can be treated first to halt progression of CKD. Several tests can be per formed to confirm a CKD diagnosis and identify its cause, but -importantly -a diagnosis requires persistence or progression of the defining abnormal ity for ≥3 months. A single GFR value or albumin uria result is insufficient and, if used for diagnosis of CKD, may lead to a high falsepositive rate for diagnosis 116 (FIG. 1) . Progression is defined according to changes in eGFR by KDIGO
.
Estimating and measuring GFR. The assessment first begins with measurement of serum creatinine concen tration under steadystate conditions and using formu lae for estimating GFR (several of which are available, such as the CKDEPI creatinine equation). The results of these creatinine based tests can be influenced by changes in muscle bulk (atrophy or hypertrophy), diet ary intake of cooked red meat and alterations in tubular secretion of creatinine owing to exposure to drugs (such as trimethoprim/ sulfamethoxazole) 117, 118 . Alternative approaches using serum cystatin C concentrations have also been proposed; although these are not influ enced by muscle bulk and diet, the cystatin Cbased Nephrotoxic agents such as antibiotics, NSAIDs, contrast media for imaging or chemotherapy can also influence risk, as can bacterial, parasitic and viral infections. Severe genetic defects that lead to FSGS, Alport syndrome, cysts and atypical haemolytic uraemic syndrome typically become evident early in life, whereas moderate genetic defects (such as mutation in uromodulin (UMOD)) can become evident in adulthood. Genetic variants in genes such as apolipoprotein L1 (APOL1) can modify the course of diseases such as lupus nephritis. formulae for eGFR can be affected by inflammation, obesity, thyroid disease, diabetes and steroid administra tion 119 . Importantly, some eGFR formulae have not been extensively validated in older people and might not apply to people of Asian or African descent 120, 121 . Demographic variables of age and sex, which might be used to correct for differences in creatinine generation, might also create unwanted complications in determining prog nostic implications of an eGFR. Newer eGFR formulae, such as the full age spectrum (FAS) equation, use serum creatin ine, cystatin C or a combination of both and have improved accuracy 122, 123 . In certain circumstances, such as when stratifying longterm risks of unilateral nephrec tomy for potential living kidney donors, measuring rather than estimating GFR can be useful 124, 125 . Although cumber some and expensive, mGFR assessments using urinary clearance methodology can sometimes be needed. However, methods of plasma clearance of the contrast agent iohexol or of radiolabelled iothalamate could avoid some of these issues.
Measuring proteinuria. Abnormal urinary excretion of albumin or total protein is essential to detect CKD when GFR is normal and contributes to the assessment of prognosis 126 . Proteinuria (or albuminuria) can be determined in several ways, including simple dipstick qualitative methods, pointofcare urinary albumin concentration tests, random urine samples to calculate the urine protein to creatinine ratio (UPCR) or the urine albumin to creatin ine ratio (UACR) or timed 24hour urine collections to measure absolute protein or albumin excretion 127, 128 -each have advantages and disadvan tages. Despite some limitations, UACR and UPCR are widely used to assess proteinuria in spot urine samples, although qualitative dipstick values can be approximated to corres ponding protein concentrations and predomin ate in primary care settings and LMICs. Urinary pro tein or albumin excretion are more variable than serum creatin ine levels, and can be influenced by posture, activity, fever or drug use; accordingly, multiple speci mens must be collected to enhance reliability. UPCR and UACR methods can be influenced by the prevailing urinary creatinine excretion rate; that is, low creatinine excretion (for example, in patients with sarco penia) can increase UPCR or UACR values even at normal abso lute protein or albumin excretion rates. Hence, adjusting for the effect of urinary creatinine excretion can enhance the accuracy of UPCR and UACR measure ments 127, 128 . In the KDIGO schema (FIG. 1) , UACR values are divided into three categories, namely, normal or moderately increased, moderately increased and severely increased 1 . Even with a normal eGFR, CKD can be diagnosed with a persistent, moderately increased UACR of >30 mg per g. Each incremental increase in UACR is associated with an increased risk of mortality and ESRD, so sustained albumin uria (or protein uria) is a powerful prognostic marker. Given that persistent proteinuria is a good pre dictor of the risk of CKD progression, albumin uria or protein uria can enable detection of CKD (see Screening, below). However, several forms of progressive CKD can present with normal or only slightly increased albuminuria or proteinuria, such as autosomal domin ant polycystic kidney disease 129 . Marked proteinuria (>3.5 g per day in adults), especially when accompanied by a reduction in serum albumin concentration (<3.5 g per dl) -the socalled nephrotic syndrome -nearly always implies a diagnosis of a primary or secondary glomerulopathy underlying CKD 130 .
Biopsy and pathology. Percutaneous kidney biopsy is a valuable tool in assessing the underlying cause of CKD. The indications for renal biopsy in a patient with CKD depend on the potential benefits (precise diagnosis, prog nostication or determination of appropriate therapy) and the risk of biopsyrelated complications. The risks of renal biopsy are minimal in experienced hands, with complications being mostly related to bleeding after the procedure. Fatal complications are rare (about 1 in every 10,000-20,000 biopsies) and major complications, such as need for nephrectomy or blood transfusion, occur in about 0.7-1.8% of biopsies [131] [132] [133] . Kidney biopsies are commonly recommended for adults with nephrotic syndrome but can also be indi cated in those with unexplained, rapidly progressive loss of kidney function, persistent haematuria and lowgrade proteinuria (0.5-3.0 g per day) or isolated proteinuria (1.0-3.0 g per day) 134 . Depending on the circumstances leading to the procedure, the pathological findings can vary widely; in those with marked proteinuria, glomerular diseases are most likely to be evident. The degree of tubulointerstitial scarring can provide useful prognostic information.
Other tests. Detection and determination of the cause of CKD also rely on renal imaging (ultrasonography, CT and MRI), careful examination of the urinary sediment and specialized biochemical and serological tests suit able to detect specific disorders that cause CKD (TABLE 1) . Imaging tests are particularly valuable as they provide information on kidney size, contours, location and density as well as information on the anatomy of the urin ary drainage system (renal pelvis, ureters and bladder). Specific lesions, such as cysts, dilatation of ureters or pelvis, calcification, masses and scars can prov ide valu able clues to the cause of CKD or confirm a speci fic diagnosis (such as autosomal dominant poly cystic kidney disease or obstructive uropathy) 135 . Urine sediment examin ation is important to detect and quantify haematuria, leuko cyturia and casts (which form in the distal tubules by aggregating components present in the tubule lumen -such as tubular cells and debris, white blood cells, red blood cells, proteins and/or lipids -into a glycoprotein matrix that is excreted into the urine).
Genetic testing is also emerging as an important tool for determining the cause of CKD, particularly in children and young adults. Autosomal dominant poly cystic kidney disease, podocytopathies causing steroid resistant nephrotic syndrome, Fabry disease and Alport syndrome are wellknown entities that can be diagnosed using genetic tests. Nextgeneration sequencing stud ies have revealed unexpected genetic heterogeneity as well as alterations in numerous different genes in a • Antiviral therapy substantial proportion of patients with these diseases (familial, syndromic and sporadic), suggesting the need to update the current diagnostic algorithms and therapeutic choices 72, 136 . Continuing advances in the field of serum and urine proteomics, microRNA biology and serology are provid ing new powerful and noninvasive tools to iden tify speci fic diseases or groups of diseases 137 . These new tools might also expand prognostication beyond GFR and proteinuria estimation -giving rise to exciting new possibilities for precision medicine tailored to the exact diagnostic and prognostic characteristics of each patient.
Screening
In the context of CKD, screening can take two forms: opportunistic screening, whereby physician encoun ters for other medical reasons can be used to screen for CKD; or population screening, for example, using dip stick urin ary testing of particular populations such as school children or military personnel. Populationbased screening can be further divided into general popula tion screening or targeted screening of highrisk popu lation groups
. Unfortunately, the benefits and harms of either screening form for CKD have not been rigorously tested in longterm prospective studies and the overall benefits and harms are poorly understood 138, 139 . Accordingly, populationbased screening for CKD is not recommended by the US Preventive Task Force largely because of insufficient evidence of benefit (or harm) 140 . However, opportunistic testing and targeted screen ing have merit, especially if other risk factors such as dia betes, hypertension or a family history of CKD are used to define the screened population. In these individ uals, eGFR and albuminuria (or total protein excretion by dipstick), UACR or UPCR should be measured. In older people with CKD G3 that has been detected by screen ing (population or opportunistic), prognosis over 5 years is typically very good. For example, a very low rate of ESRD (0.2%) and stable CKD or remission of CKD was found in 53% of such people (mean age of 73 years at study entry) after 5 years of follow up 141 . This low rate of ESRD raises questions regarding the efficiency and costeffectiveness of populationbased screening for CKD in the elderly as a means of reducing the overall societal burden of treated ESRD.
Evidence in favour of targeted screening is stronger, but still incomplete. Given that early treatment might impart substantial effects on delaying CKD progression and progression to ESRD 142 , targeted screening strategies using albuminuria in those with diabetes or hypertension might be of benefit; indeed, Monte Carlo simulations of probabilities support such an approach 143 . Some studies have also suggested that testing for abnormal albumin uria is an efficient way to identify and stratify individuals who are at risk of progressive CKD and cardiovascular events 144 . Indeed, abnormal proteinuria (even only slightly above the upper limit of normal) identifies people at increased risk of ESRD and/or cardiovascular morbidity and mortality 145 . Other atrisk individuals might include firstdegree relatives of a patient with autosomal domin ant polycystic kidney disease, who are eligible for screen ing with renal ultrasonography or MRI regardless of their eGFR or proteinuria results. Siblings of patients with Fabry disease, Alport syndrome or thin basement mem brane nephropathy might benefit from genetic analy sis as well. African Americans with hypertension or HIV infection could gain moredetailed prognoses through assessment of APOL1 risk alleles, but populationbased screening for APOL1 risk alleles is not yet justifiable 146 . Both general population screening and targeted screening for CKD are logistically hampered by the need for re evaluation at a defined interval to fulfil the KDIGO duration requirement (3 months) for diagnosis and staging of CKD. Thus, oneoff testing using eGFR or protein uria have high falsepositive detection and diag nosis rates that can be further confounded with the use of nonagesensitive eGFR thresholds
. The poten tial harms of general population screening include exces sive followup diagnostic procedures (including renal biopsy, with its associated risks), unnecessary referral of individuals erroneously diagnosed as having CKD, the anxiety induced by being labelled as having CKD and potential impact on insurability. Accordingly, the American College of Physicians determined that cur rent evidence was insufficient to evaluate the benefits (or harms) of populationbased or targeted screening for CKD 147 . However, several other countries have long established programmes (for example, Japan Going forward, general population screening needs to take into account the agespecific likelihood of find ing CKD, the effectiveness of treatment of limiting CKD progression to ESRD once found (or the occurrence of premature death) and the overall costeffectiveness per qualityadjusted life years (QALY) gained. In using a Markov decision analysis model, Boulware et al. 153 showed that annual screening for CKD by dipstick protein uria in persons without hypertension or diabe tes was not costeffective ($282,818 per QALY gained), although the costeffectiveness improved in people >60 years of age. By contrast, screening in those with hypertension or diabetes was costeffective, particularly for a death benefit 153 . Furthermore, the overall cost effectiveness of periodic screening for reduced eGFR alone, independent of proteinuria, is largely unknown as studies are lacking, but would be expected to be cost ineffective; similar conclusions were reached in a system atic review by Komenda et al. 154 in 2014. Accordingly, lessfrequent screening, inclusion of older people only and/or screening of popu lations with increased incidence of proteinuria could form the basis of a costeffective screening strategy.
Prevention
Primary prevention before CKD is established and second ary prevention to slow the rate of CKD progres sion (or to affect the associated comorbidities or com plications; see below, Management) can be considered. Both are more preferable than afterthefact treatment with renal replacement.
Primary prevention targets the root causes of CKD and includes mitigating exposures to nephrotoxic agents and events
. Reducing the burden of infec tious diseases (such as HIV, malaria and Streptococcus infections) can reduce rates of CKD, but many challenges remain in the quest to reduce the prevalence of CKD by interventions directed at noncommunicable diseases. For example, preventing obesity and the associ ated type 2 diabetes mellitus is a global challenge 155 , but the discovery of the central role of sugar and fructose intake and metabolism in obesity can be cited as an example of progress with implications for primary prevention. Indeed, better glycaemic control might also eventually prevent CKD and its progression 142, 156 . Other dietary factors could be modifiable risk factors to be targeted for primary prevention. For example, excessive sodium intake in patients with hyperten sion can influence blood pressure control and perhaps aggrav ate glomerular hyperfiltration. Excessive protein intake in diabetes can promote hyperfiltration and pre dispose to CKD. In this regard, strict vegetarian diets with low dietary acid load have been associated with lower CKD burden in observational retrospective studies 157 and might be useful as preventive strategies. However, observational studies of the impact of diet quality and composition on CKD incidence have been inconsistent [158] [159] [160] [161] . Large prospective cohort studies have suggested that 'healthy' dietary patterns are associated with fewer renal deaths and lowered incidence of ESRD, but causality remains unproven 162 . Increased vegetable and fruit intake with restricted red meat consumption has been associated with a lower incidence of CKD in case-control cohort studies, but these studies are subject to confounding by unmeasured variables so they cannot prove causality 163 . A major focus of interest has been on the influence of acid-base homeostasis on the development and progres sion of CKD 164 . So far, these studies have primarily exam ined the deleterious influence of metabolic acidosis on the progression of established CKD (secondary preven tion of ESRD) rather than prevention of incident CKD 165 . Indeed, low serum bicarbonate and high diet ary acid load (as assessed by net urinary acid excretion) has been shown to be associated with ESRD risk among patients with established CKD 164, 165 . Furthermore, in those with diabetes, a low capacity for acid excretion might influence CKD progression independent of diet ary acid load 166 , which implicates metabolic acidosis in the progression of established CKD. This finding led to a random ized controlled trial of the safety of oral bicarbon ate supple mentation in those with moder ate to severe CKD, which is recruiting at the time of writing (the BASE study, NCT02521181). To our know ledge, no studies are cur rently examining whether oral bicarbon ate supplemen tation can prevent the occurrence of CKD in otherwise healthy people of any age.
Improved recognition and reduction of the preva lence of AKI should also prevent CKD, especially in regions where AKI is common, underrecognized and undertreated (such as in equatorial Africa). Given the importance of low nephron endowment, fetal mal nutrition and/or dysmaturity manifested by low birth weight, global efforts to reduce fetal malnutrition and dysmaturity should have enormous preventive effects in later years; focused effects are beginning to address this important topic 61 .
Management
Several aspects need to be considered when managing patients with CKD, including controlling further nephron injury, normalizing singlenephron hyper filtra tion, controlling CKDrelated complications and prepar ing the patient for kidney replacement therapy (TABLE 1) . At the core of these is the principle of 'the earlier, the better' , which is the effort to reduce the progression to ESRD and optimize renal outcomes. To achieve this, a systems level approach to patient and physician education has been undertaken by numerous organizations
The benefits of early therapy are well documented for Alport syndrome 167 . Initiating RAS blockade after a genetic diagnosis but before any signs of kidney disease can have dramatic effects on renal outcomes, whereas initiating RAS blockade once CKD G3 is evident only somewhat delays progression to ESRD 167 (FIG. 7) . Further support comes from a post hoc analysis of clinical trial data of RAS blockade in diabetic kidney disease; the gain of ESRDfree years was highest when RAS blockade was initiated at the time of microalbuminuria identification and lowest when initiated once a diagnosis of CKD G3 or G4 was made 168 . Thus, early diagnosis and treatment are essential to prevent nephron loss as early as possible.
Controlling ongoing nephron injury
Nephron injury can be driven by numerous triggers, and abrogating these triggers will slow progression to CKD and ESRD (TABLE 1) . Specific cures for genetic kidney diseases exist and are mostly limited to enzyme replacement therapy or substrate supplementation. The genetic basis of immunemediated nephron injury is not yet fully explored, but progression of CKD associ ated with C3 glomerulonephritis or atypical haemolytic uraemic syndrome can be controlled with complement inhibitors 169 . Most acute forms of immunemediated nephron injury present either as vasculitis, immune complex glomerulonephritis or interstitial nephritis (including allograft rejection). These disorders can often be targeted with immunomodulatory drugs (and some times with plasma exchange) to limit nephron loss from attack by the humoral and/or cellular elements of the immune system 170 . By contrast, in smouldering immune injury, such as in chronic IgA nephropathy, it is difficult to dissect CKD progression driven by immune versus non immune mechanisms and the effectiveness of immuno suppres sion versus RAS blockade and blood pressure control is less evident 171 . Kidney biopsy can establish the under lying diagnosis and guide management by assessing the ongoing activity of immune injury versus irreversible damage in, for example, lupus nephritis, IgA nephro pathy or allograft dysfunction. Specific treatments are also available for CKD related to urinary tract obstruc tion, infections and some forms of toxic injury. However, even with complete abrogation of the injurious trigger, recovery of lost nephrons is impossible.
Avoiding further episodes of AKI is crucial to min imize stress on the remnant nephrons in CKD. This implies patient education on avoidable nephrotoxins (such as large volumes of radio contrast media, NSAIDs, certain antibiotics, possibly proton pump inhibitors or other endemic or occupational toxins). Hypovolaemic states as well as urinary outflow obstruction should be avoided. Additionally, asymptomatic leukocyturia alone might not imply bacterial infection, and antibiotic treatment should be limited to cases in which dysuria, bacteri uria and leukocyturia indicate infection. Smoking cessation is essential to minimize CVD 172 .
Normalizing single-nephron hyperfiltration
Rigorous RAS inhibition with angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) has the capacity to substantially reduce GFR (singlenephron) and glomerular filtration pressure, which leads to a decline in not only proteinuria but also total GFR -and, hence, moderately increases serum creatin ine levels 173 . At first, this serum creatinine increase is worrisome to patients (and physicians) and requires clarification that reducing hyperfiltration in remnant nephrons is the central strategy to retard CKD progres sion in patients with proteinuria. By contrast, ACEi or ARBs do not retard the progression of nonproteinuric forms of CKD such as autosomal dominant poly cystic kidney disease but might benefit on the associated cardio vascular complications 174 . ACEi or ARBs should be titrated to the maximal possible dose, whereas hyper kalaemia can be corrected using loop diuretics (which act at the ascending limb of the loop of Henle) or potassium binding resins 175 . A moderate increase in serum creati nine levels indicates a decline in GFR (singlenephron) , which is a powerful predictor of the intended nephroprotective effect 176 . Numerous randomized clinical trials have docu mented that RAS inhibitors can retard or even halt CKD progression 42 . Reducing dietary salt and drugs that sup port the control of blood pressure and hyperlipidaemia, often referred to as the 'remission clinic protocol' , can fur ther reduce proteinuria and retard CKD progression 177, 178 . Such interventions are affordable and are essential when kidney replacement therapy is not available or affordable.
Next, blood pressure targets remain an area of debate. A subgroup analysis of the Systolic Blood Pressure Intervention Trial documented reduced rates of major cardiovascular events and allcause death when a sys tolic blood pressure <120 mmHg was reached (compared with <140 mmHg) in patients with CKD and hyperten sion without diabetes 179 . However, these effects might not apply to patients with CVD who are susceptible to compensatory neurohumoral stimulation and sudden cardiac death upon tight blood pressure control. Blood pressure target levels also depend on the method of blood pressure measurement.
Finally, lifestyle modifications such as avoiding or correcting obesity can also reduce filtration load and glomerular hypertension; hence, a normal BMI is a treat ment target to retard CKD progression 180 . However, any immunosuppressionrelated benefit of using steroids in CKD can be counterbalanced by steroidrelated obesity Box 3 | System-level approaches to CKD Several health care systems have population-based programmes to assure awareness of the public to chronic kidney disease (CKD) or to ascertain certain standards of care for patients with CKD among health care providers. For example, the US CKD Surveillance Project of the US Centers for Disease Control and Prevention provides focused information about all aspects of CKD prevalence, populations at risk, health consequences, quality of care and health care system capacities (nccd.cdc.gov/ckd/). In Canada, the Alberta Health Services host a strategic clinical network to achieve excellence in sustainable quality kidney care and outcomes through innovation and evidence-based practice that focuses on prevention, early identification and appropriate management across all ages and stages of CKD (www. albertahealthservices.ca/scns/kidneyhealthscn.aspx). Many health care providers offer information with the opportunity of support via online forums, such as the UK National Health Care System Choices platform (www.nhs.uk/conditions/kidney-diseasechronic/pages/introduction.aspx) or the National Kidney Disease Education Program by the US National Institute of Diabetes and Digestive and Kidney Diseases (www. niddk.nih.gov/health-information/health-communication-programs/nkdep/Pages/ default.aspx). Private organizations, often endorsed by patient groups, exist in many countries and flank governmental services with patient-oriented support. For example, Kidney Health Australia is a not-for-profit organization devoted to promoting good kidney health through education, advocacy, research and support programmes such as camps for children with kidney disease and housing programmes for those undergoing kidney transplant and their families (www.kidney.org.au). The Kidney Education Foundation supports patient education around the world and has published a book on kidney health that is freely available (www.kidneyeducation.com). The book is available in 31 languages (including many spoken in low-resource settings) and endorses patient education, particularly in regions where disease management programmes might not exist or are inaccessible to many patients.
that drives glomerular hyperfiltration and secondary FSGS, which could explain why steroid treatment falls short in retarding progression of IgA nephropathy related CKD 171 . Additionally, concomitant diabetes has important implications for CKD management 181 . Hyperglycaemia maximizes glomerular hyperfiltration via SGLT2driven vasodilation of the afferent arteriole of the remnant nephrons, which cannot be controlled by RAS inhibitors 84 . Accordingly, SGLT2 inhibitors can reverse this process and elicit profound additive nephro protective effects on CKD progression 88, 182 ; their capacity to also reduce CVD in patients with type 2 diabetes 182, 183 provides a strong rationale for dual RAS and SGLT2 blockade in patients with diabetes and CKD.
Controlling CKD complications
CKD is associated with a number of secondary com plications that require management (BOX 4) , the most relevant of which in terms of overall mortality is CVD 34 . Cardiac and vascular alterations also arise from endo crine failure (for example, a lack of erythropoietin, vita min D or PTH), which causes anaemia and secondary hyperparathyroidism 184 . Myocardial fibrosis is the final consequence of the multiple underlying causes.
Large randomized controlled trials in patients on haemo dialysis have tested a number of different interven tions intended to reduce cardiovascular events, includ ing frequency and length of dialysis sessions and flux (filtration coefficient of the membrane in the dialyser), erythropoietinstimulating agents, statins, RAS blockade, folic acid, cinacalcet (a calcium mimetic used to treat second ary hyperparathyroidism) or vitamin D deriva tives but have largely been unsuccessful [185] [186] [187] . For exam ple, reduction of lowdensity lipoprotein cholesterol with simvastatin (a statin) plus ezetimibe (which decreases cholesterol absorption) reduced the incidence of major atherosclerotic events more efficiently in patients with CKD G2-G4 than in patients with CKD G5 or who were on dialysis 187 . Guidelinedirected approaches on the basis of diabetic status aim to achieve target blood pressure through administration of RAS blockers, salt restriction and anaemia prevention 188, 189 . Guidance is also avail able to correct acidosis, as well as to assess and manage CKD-MBD 190 
Preparing for kidney replacement therapy
Once the stage of ESRD is reached, renal replacement therapy is usually required, although conservative treat ment is a potential alternative option, especially in older adults with limited lifespan. Counselling on the options (kidney transplant, haemodialysis, peritoneal dialysis or no dialysis) should be coordinated by the nephrologist and involve a multidisciplinary team that includes the general practitioner. Early counselling is essential because informed patients are better prepared to face kidney fail ure. Indeed, late referral at the time of ESRD is associated with worse health status at the time of kidney replace ment therapy initiation, higher mortality after starting dialysis and reduced access to transplant 191 . Although practical equations are available to pre dict CKD progression 192 , one of the greatest challenges nephrologists face is to predict kidney disease progres sion, which does not follow a steady linear decline. This unpredictability often becomes a barrier to timely shared decision making between patients and physicians 191 and can offset the early predialysis nephrology care for adults with latestage CKD and compromise outcomes 193 . KDIGO recommends the initiation of dialysis when symptoms or signs of kidney failure are evident 1 (typi cally when GFR is 10-5 ml/min/1.73 m 2 ). Preemptive (that is, before dialysis initiation) living donor renal transplantation should be considered in individuals with GFR <20 ml/min/1.73 m 2 and evidence of progressive CKD over the preceding 6-12 months 1 .
Haemodialysis. Preparing patients for haemodialy sis, which uses pumps, membranes and dialysates to clear uraemic toxins from the blood, involves refer ral for vascular access placement. The types of access include arteriov enous fistulae, arteriovenous grafts and central venous catheters (which are for shortterm use) (FIG. 8a-c) ; arteriovenous access is the preferred option for haemodialysis, although there is no consensus about the optimal timing for creation, especially for arterio venous fistulae 194 . To protect the blood vessels for per manent vascu lar access, attention should be taken to avoid venous puncture or intravenous catheter placement proximal to the wrist, which preserves venous access at the back of the hand. Arteriovenous access (either fistulae or grafts) is associated with better outcomes than cen tral venous catheters 195, 196 , as is conversion from central venous catheter to arteriovenous access 197 . Thus, a func tional arterio venous access is preferable for all patients in whom this is possible.
Peritoneal dialysis. Peritoneal dialysis uses the perito neal membrane as an exchange interface to clear urae mic toxins from the blood. For this, a transcutaneous catheter is implanted into the peritoneal cavity that can be drained daily and used to refill dialysate fluid. After some hours of reaching equilibrium between uraemic blood and fresh dialysate, each dwell is expected to drain excess fluid and metabolic waste products including uraemic toxins (FIG. 8d) ; whether these affect patient out comes remains unclear. Patients starting on peritoneal dialysis show better initial outcomes and preservation of residual renal function in the first 2 years, compared with patients on haemodialysis but these differences normalize after 2 years 199 .
Kidney transplantation. When available, suitability for kidney transplantation should be evaluated according to age and comorbidities, but it can take months to com plete 200 . Comorbidities such as cancer, chronic infec tions, cardiac or peripheral vascular disease and the risk of medical noncompliance are carefully evalu ated in this process. Depending on the regional ratio of donors to recipients and on allocation rules, waiting time for a deceased donor kidney can vary from a few months (in Belgium and Austria) to many years (in Germany). Thus, the option of living kidney donation should be explored.
To test for eligibility, potential donors must undergo a comprehensive health assessment including tests for blood group and human leukocyte antigen compatibil ity with the potential recipient, GFR measures, imaging of the kidneys and the urinary tract, cardiac testing and other tests depending on the medical history. Such rigor ous testing is recommended to ensure the shortterm and longterm wellbeing of the donor after donation. Preemptive transplantation can offer several benefits to patients with ESRD, but its benefits remain under evalu ation 201 . The halflife of a transplanted kidney is <20 years, making these patients also potential candidates for CKD treatments during their lifespan 202 . For example, recur rent glomerulonephritis is an unpredictable complication that can have a negative impact on graft outcome 203 .
Conservative treatment and palliative care
Kidney replacement therapy might not be available or affordable but it also might not be advisable for medical reasons. Particularly in very old patients with ESRD and comorbidities, dialysis might neither increase lifespan nor improve quality of life (QOL) [204] [205] [206] . In such patients, palliative care that aims to control the symptoms of urae mia that negatively affect QOL 207 and education starting at CKD G4 that aims to explain comorbidity manage ment might be appropriate. Withdrawal from dialysis is a related issue and is common in very old patients receiving haemodialysis 208 .
Box 4 | Key strategies to managing CKD complications
Renal anaemia
• Erythropoiesis stimulating agents (ESAs) are given only when all correctable causes of anaemia (such as iron deficiency and inflammatory states) have been addressed 188 • Adults receive iron supplementation when transferrin saturation is <30% and ferritin <500 ng per ml; children (<18 years) receive iron supplementation when transferrin saturation is <20% and ferritin <100 ng per ml 188 • ESAs can be used to avoid haemoglobin levels that are <9.0 g per dl, with a maximum target of 11.5 g per dl 188 • Avoid blood transfusions, especially in potential transplant recipients to avoid sensitization and ESAs should be avoided in those at risk of stroke or who have malignancy ) and NaCl intake (<5 g per day) 189 • Take regular physical exercise and limit alcohol intake to two drinks per day in men and one drink per day in women
189
Mineral bone disorder • Monitor calcium, phosphorus, parathyroid hormone (PTH) and alkaline phosphatase activities in adults beginning at CKD G3a and in children beginning at chronic kidney disease (CKD) G2; 25-hydroxyvitamin D levels might also be measured and corrected in these populations using vitamin D supplementation as for the general population 190 • In CKD G3a-G5 (including those on dialysis), lower elevated phosphate levels towards the normal range but avoid hypercalcaemia by restricting the dose of calcium-based phosphate binders 190 • Avoid long-term exposure to aluminium in phosphate binders or dialysate 190 • Measure bone mass density in patients with CKD G3a-G5 (including those on dialysis) who show evidence of bone disease to assess fracture risk 190 • In adults, 25-hydroxyvitamin D and vitamin D analogues are no longer recommended for routine use unless secondary hyperparathyroidism in CKD G4-G5 is severe and progressive 
Metabolic acidosis
• Oral bicarbonate can be used to correct mild metabolic acidosis
Chronic hyperkalaemia
• Dietary potassium restriction should be implemented • Loop diuretics and potassium-binding resins should be administered, or dose adjustments of renin-angiotensin system (RAS) inhibitors and aldosterone antagonists must be considered
Quality of life CKDrelated symptoms increase as CKD progresses and are key drivers of poor QOL in patients with CKD and ESRD [209] [210] [211] . Although symptoms rapidly improve with kidney transplantation, these are most severe in patients on dialysis, who frequently report fatigue, nausea, dyspnoea, anorexia, pruritus, restless legs and cramps 212 . Pain is especially common: in a survey of 205 patients undergoing haemodialysis, ~25% had severe pain during the 24 hours preceding the interview and an additional 12% had moderate pain 213 . Mental illnesses, including depression and anxiety, are also common 214 but are understudied among people with CKD.
Unfortunately, clinical and epidemiological charac ter istics associated with the presence, severity, onset and remission of uraemic symptoms are incompletely described, their pathophysiology is poorly under stood and few drugs have been approved by regulatory authorities for their treatment 215 . A key barrier for better manage ment of uraemic symptoms is lack of information about the link between body levels of uraemic toxins and the specific symptoms that patients experience; speci fic toxin patterns might correlate with symptoms and could be addressed with targeted blood purification strat egies. Studies evaluating this paradigm should be a high priority for researchers and funders.
Comorbidities and complications of CKD also sub stantially contribute to the reduced QOL in CKD patients. For some, such as anaemia, effective treatments are available, but for others, treatment has major limita tions or can cause additional symptoms and morbidity (for example, the dialytic management of hypervol aemia). Despite the best efforts of clinicians, inter actions between complications and their treatments can further compromise QOL for patients (for example, hyper volaemia resulting from sodium bicarbonate treatment for acidosis). Management of multiple comorbid condi tions is already complex in patients with normal kidney function 216 ; the situation is even more challenging in people with CKD, in whom the pathophysiology and optimal treatment of common coexisting conditions can differ from the general population. Lack of knowledge of how to prioritize and manage comorbid conditions undoubtedly contributes to the lower QOL in CKD patients through multiple mechanisms -including drug-drug and drug-condition interactions, pill burden and decisional conflict for patients.
Key challenges for haemodialysis that specifically compromise QOL include poor functional status (driven in part by procedurerelated immobilization, uraemiarelated malnutrition and muscle wasting), the intrusive and timeconsuming nature of the treat ment and vascular access infection and dysfunction 217 . Instruction for some homebased, low intensity phys ical exercise can improve physical performance and QOL in patients on haemodialysis 218 . Peritoneal dialysis also poses major challenges for QOL, including gastro intestinal distension, hernia and chronic hypervolaemia. Both forms of dialysis make employment difficult and both are associated with high rates of infectious com plications and undue pill burden. Some studies sug gest that peritoneal dialysis is associated with slightly better QOL than haemodialysis 219 , but it is possible that this observation is confounded by patient selection 220 . Home dialysis strategies are constantly improving and are becoming possible tools to improve QOL 221 . Kidney transplantation is associated with substantially better QOL than either form of dialysis 222 , but even recipients with good graft function must face CKDrelated symp toms as well as complications of immunosuppression and other treatments.
In addition, findings from contemporary patient centred research should help to drive uptake of patient centred care at the bedside, especially if supported by patientreported outcomes 223 . Such paradigm shifts should help to prioritize the management of patientimportant issues such as reduced QOL. The increased flow and perfusion pressure leads to structural modifications in the draining vein that enables repetitive venous puncture for haemodialysis. Occasionally declining blood flow to the hand and fingers (steal phenomenon), compensatory increases in cardiac output or aneurysm formation cause problems and require surgical correction. b | Arteriovenous grafts might be necessary when the patient's vascular status does not support a fistula. Polytetrafluoroethylene grafts are mostly used and can be repetitively punctured for haemodialysis. Common problems are sterile inflammatory postimplantation syndromes or prosthetic graft infections causing bacterial sepsis. c | Central venous catheters become necessary when immediate initiation of renal replacement therapy is needed until a fistula or graft implant becomes ready for use. Such catheters remain the only vascular access option for patients in whom fistula or graft placement is not possible. Catheter infections or thrombotic complications remain constant concerns. d | Peritoneal dialysis requires placement of a transcutaneous catheter into the peritoneal cavity, which enables the filling, draining and refilling of dialysate (usually four times a day). The peritoneum serves as an exchange membrane with the uraemic blood. 27 ; here, we expand on some of the most promising domains.
Genetic kidney disease contributions to CKD
Nextgeneration sequencing studies have unveiled the extreme genetic heterogeneity of kidney disease, with, for example, >40 different genes identified as possible causes of steroidresistant nephrotic syndrome 136 . These data should be integrated into diagnostic strategies that go beyond the renal biopsy to enable personalized diagnosis and treatments 136 .
With this in mind, study of the genetic predisposi tion to kidney diseases has made major progress over the past decade. Genomewide screens and associ ation studies have identified genetic susceptibility variants, mapped risk loci and provided the basis for the projection that the genetic forms of CKD will increase exponentially alongside our understanding of the genetic component of kidney function in health and disease 224 .
Biomarkers for CKD management
Earlier identification CKD with biomarkers that can also predict CKD progression would help to initiate nephroprotective interventions 27 . Most attractive would be a marker of nephron number. Defining nephron number at birth would identify low nephron endow ment and help to dissect endowment from injury related or ageing related nephron loss later in life. Such a marker could also detect CKD G2, and could serve as an end point parameter for clinical trials to quantify nephroprotective effects and drug toxicity. However, identify ing a clinically applicable biomarker of nephron number in serum or urine has been unsuccess ful so far. Bio markers do not clearly discriminate neph ron number from the compensatory remnant nephron hyper trophy. Imaging studies using tracers or the com bin ation of imaging with kidney biopsy to indicate the number of glomeruli (or GFR (singlenephron) ) are promising proofofconcept strategies 76, 225 .
Triggers of nephron loss and CKD progression
Dissecting the relative contributions of low nephron endowment, nephron injury, wound healing (inter stitial fibrosis) and compensatory hyperfiltration to CKD remains notoriously difficult. Furthermore, to what extent fibrosis itself contributes to nephron loss remains under debate, and several antifibrotic drugs are under study to test this concept 226, 227 . Finding ways to define the contributions of these factors and selectively target them in a personalized manner will remain a research focus in the coming years.
Modifying CKD progression
Aside from targeting fibrosis to slow CKD progres sion, uratelowering therapies are also being explored. Such agents have already showed promising results in small trials and the results of an ongoing multicentre trial are eagerly awaited 228 . Additionally, the nuclear factor erythroid related factor2 agonist bardoxo lone and folic acid supplementation have shown nephroprotective effects in randomized clinical trials in some patient populations in a dosedependent manner, although the mechanisms of action are not yet fully understood 186, 229, 230 .
Nephrogenesis and regeneration
Given the substantial hurdles in accessing renal trans plantation, current work is exploring the regeneration of injured nephrons (FIG. 9) . For this to be a viable option, a growing research field is trying to unravel the physio logy and pathophysiology of the intrinsic capacity of the nephron to regenerate.
Several studies have identified possible druggable targets to prevent nephron loss in AKI and CKD 231 . For example, targeting parietal epithelial cells that act as progenitors to podocytes to promote their differenti ation into fully functional podocytes and/or to block their excessive proliferation and matrix production might promote remission of glomerular dis orders [232] [233] [234] . In addition, enhancing tubular regeneration by promo ting tubular epithelial cell proliferation can reduce the occurrence of CKD after AKI 233, 235 . Although in vivo experimental studies seem promising, no clin ical trials are available yet [232] [233] [234] . Finally, several early (phase I-II) clinical trials are looking at inhibiting maladaptive repair mechanisms to ebb nephron loss in CKD 236 . Other antifibrotic drugs are also being tested in clinical trials 233, 236, 237 . Regenerative medicine is also being explored to treat kidney disorders. For example, mesenchymal stroma cells (MSCs) -a population of well characterized, easily obtainable cells -have improved kidney func tion and structure in experimental models of CKD 238, 239 . MSCs impart immunomodulatory and paracrine effects, secreting microvesicles and/or exosomes that deliver genes, microRNAs and proteins to recipient cells; these are currently being tested in early (ongoing or recently closed) clinical trials (NCT02012153, NCT02166489 and NCT02585622). Similarly, numerous experimen tal studies have reported improvement of kidney func tion and/or structure by activating tissuebased renal progenitor cells injected into different mouse models of AKI as well as CKD [231] [232] [233] [234] [235] . However, the translation of preclinical studies into robust, effective and safe patient therapies remains limited 232, 233, 236 . Finally, the generation of 3D organ buds termed 'organoids' from human induced pluripotent stem cells and embryonic stem cells has been achieved for the kidney; these organoids consist of a variety of renal cell types in vitro that mimic organs in vivo 240, 241 . The organoids can be used to study human diseases and testing of drug toxicity in vitro, especially when combined with CRISPR-Cas9based genomeediting techniques 242, 243 . However, the complex kidney struc ture and function are far from being recapitulated for clinical use, and the question remains whether a ' laboratorygrown' kidney will ever be possible.
Limiting cardiovascular morbidity and mortality
Targeting the association of CKD with cardiovascular morbidity and mortality will require additional, rigor ous functional studies in animals and humans to identify molecular targets that are suitable for therapeutic inter vention 27 . Controlling hyperlipidaemia by modulating lipid transport (for example, with proprotein conver tase subtilisn/kexin type 9 inhibitors), suppressing sys temic inflammation (with innovative antiinflammatory drugs such as complement inhibitors), modulating the intestinal microbiota (with probiotics to limit micro biotarelated systemic inflammation and dysfunctional metabolism) or interfering with vascular calcification and cardiac fibrosis (with vitamin K analogues) could offer new solutions for this imminent problem in the future.
Animal models
Innovative approaches to better link translational research to clinical trial findings will need to start with welldefined human genotypes and phenotypes to iden tify molecular targets, which could subsequently be valid ated in animal models. Selection of such animal models for validation should be based on models that recapitu late CKD progression in humans and should require identical end points in subsequent clinical trials. Such models might include mice with identical pathogenetic mutations as in human disease, mice with a humanized immune systems or models in higher animals (such as pigs or nonhuman primates) that can be used to close the 'gaps' between preclinical and clinical trials 244, 245 .
Clinical trial design
Patient heterogeneity is considered one of the main reasons why clinical trials in nephrology commonly fail 246 . Indeed, in adults, a CKD diagnosis might be the consequence of several contributing factors that have accumu lated over time, such as APOL1 or UMOD vari ants (which modify CKD progression), low nephron endowment or AKI episodes earlier in life. Such com plexity has important implications for the design of CKD trials that necessitates the characterization of homo gen eous patient subgroups. The ensuing tar geted clinical trials will require fewer participants and increase the possibility of identifying appropriate drugs for different patients.
Trial design could be improved by reconsidering dis ease entities defined by descriptive histological features without causative clues such as FSGS, avoiding addon designs that incorporate drugs with redundant mech anisms of action, preselecting patients on the basis of biomarker profile and studying end points that better predict CKD progression to ESRD. For example, to test the efficacy of the complement 5a receptor (C5AR) inhibitor avacopan in patients with antineutrophil cytoplasmic antibody (ANCA) vasculitis, the CLEAR trial at first avoided the usual addon standard of care approach and instead compared avacopan plus low dose steroids versus placebo plus highdose steroids on top of either cyclophosphamide or rituximab 247 . This strategy enabled researchers to prove that avacopan was effective in replacing highdose glucocorticoids in treating vasculitis.
Translation of advances into daily practice
The evergrowing complexity of interpreting kidney biopsy (pathology) findings, assessing laboratory diag nostics and integrating genetic testing will require Figure 9 | Targeting kidney regeneration. In the future, it may be possible to target kidney regeneration and maladaptive repair to minimize the loss of injured nephrons and to protect the remnant nephrons. The most promising areas of research include enhancing podocyte regeneration (which could be achieved using drugs such as glycogen synthase kinase 3β (GSK3β) inhibitors, steroids or steroid receptor antagonists that promote differentiation of parietal epithelial cell (PEC) progenitors into podocytes and/or block the excessive proliferation of PECs), blocking fibrosis and/or maladaptive repair by inhibiting fibroblast expansion (which could be achieved using the antifibrotic drug pirfenidone, inhibitors of the transcription factor zinc-finger protein GLI2 or antagonists of the fibrotic mediator galectin 3) and enhancing tubular regeneration (with IL-22 or histone deacetylase (HDAC) inhibitors, which enhance tubular cell proliferation) [232] [233] [234] [235] [236] [237] . miR, microRNA; SDF1, stromal cell-derived factor 1. . Global guidelines created by the KDIGO initi ative have become instru mental in this process, starting from a global defin ition of CKD stages up to defining standards for the manage ment of CKD complications but these must be refined and improved as our knowledge increases. 
